心力衰竭中的性别差异
本文综述了男性与女性在心衰总体终生风险相似背景下,于心衰类型、病理生理、治疗反应及预后方面存在的显著性别差异。男性易患射血分数降低的心衰(HFrEF),女性则以射血分数保留的心衰(HFpEF)为主。文章提出大血管冠心病/心肌梗死易感可能解释男性HFrEF高风险,而冠脉微血管功能障碍/内皮炎症可能在HFpEF及女性易感的Takotsubo心肌病、围产期心肌病和乳腺癌放疗诱导心肌病中起关键作用。
要点
- 男性以HFrEF为主,女性以HFpEF为主,终生风险总体相似。
- 女性在心衰临床试验中仅占20-25%,治疗指南主要基于男性数据。
- 冠脉微血管功能障碍/内皮炎症可能是女性易感HFpEF及特定心肌病的共同 link。
核心结论
- 心衰存在重要且未被充分认识的性别差异,涉及临床特征、病理生理、治疗反应和预后。
研究设计与样本
- 综述,检索范围未在摘要中明确报告。
主要发现
- 男性易患HFrEF,女性以HFpEF为主。
- 遗传性心肌病的外显率、风险因素(如乳腺癌及其治疗相关心肌病)及性别特有疾病(如围产期心肌病)存在性别差异。
- 女性在心衰临床试验中仅占队列的20-25%。
- 男性HFrEF风险较高可能归因于大血管冠心病和心肌梗死易感,冠脉微血管功能障碍/内皮炎症可能在HFpEF及女性易感心肌病中起关键作用。
临床怎么用
- 临床应认识心衰的性别差异,但治疗指南主要基于男性数据,女性最佳药物剂量和器械治疗性别特异性标准存在知识缺口。
局限性
- 女性临床试验招募不足(20-25%),性别特异性机制、女性最佳药物剂量及器械治疗性别特异性标准存在重大知识缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The overall lifetime risk of heart failure (HF) is similar between men and women, however, there are marked sex differences in the landscape of this condition that are both important and under-recognized. Men are predisposed to HF with reduced ejection fraction (HFrEF), whereas women predominate in HF with preserved ejection fraction (HFpEF). Sex differences are also notable in the penetrance of genetic cardiomyopathies, risk factors, e.g. breast cancer which may be associated with cancer treatment-induced cardiomyopathy, as well as sex-specific conditions such as peripartum cardiomyopathy (PPCM). This review outlines the key sex differences with respect to clinical characteristics, pathophysiology, and therapeutic responses to HF treatments. Finally, we address important differences in the prognosis of HF. A central hypothesis is that the higher risk of HFrEF in men compared to women may be attributable to their predisposition to macrovascular coronary artery disease and myocardial infarction, whereas coronary microvascular dysfunction/endothelial inflammation has been postulated to play a key role in HFpEF and maybe the common link among HF syndromes that women are predisposed to Takotsubo cardiomyopathy, PPCM, and breast cancer radiotherapy-induced cardiomyopathy. Under-pinning current sex disparities in HF, there is a paucity of women recruited to HF clinical trials (20-25% of cohorts) and thus treatment guidelines are predominantly based on male-derived data. Large gaps in knowledge exist in sex-specific mechanisms, optimal drug doses for women and sex-specific criteria for device therapy.
引用
- Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. Eur Heart J. 2019. PMID: 31800034. doi:10.1093/eurheartj/ehz835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。